Citations

Clear

6273 citation(s) found for "To, Andrew".

Mutation Type Is Not Clinically Useful in Predicting Prognosis in Hypertrophic Cardiomyopathy
Landstrom, Andrew P. , Ackerman, Michael J. , Landstrom, Andrew P

Mayo Clinic

Circulation | December 6, 2010 | Volume: 122 | Issue: 23 | Pages: 2441-2450

10.1161/circulationaha.110.954446 | PMID 21135372 Get It

Obesity and Breast Cancer Prognosis: Weight of the Evidence
Dannenberg, Andrew J. , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | November 30, 2010 | Volume: 29 | Issue: 1 | Pages: 4-7

10.1200/jco.2010.32.1752 | PMID 21115867 Get It

A Practical Guide to Fetal Echocardiography: Normal and Abnormal Hearts, 2nd ed.
Bowman, Andrew W.

Mayo Clinic

American Journal of Roentgenology | November 22, 2010 | Volume: 195 | Issue: 6 | Pages: W479-W479

10.2214/ajr.10.4870 Get It

Shock Wave Lithotripsy is Not Predictive of Hypertension Among Community Stone Formers at Long-Term Followup
Krambeck, Amy E. , Li, Xujian, Bergstralh, Eric J., Gettman, Matthew T., Rule, Andrew D. , Lieske, John C.

Mayo Clinic

Journal of Urology | November 14, 2010 | Volume: 185 | Issue: 1 | Pages: 164-169

10.1016/j.juro.2010.09.033 | PMID 21074794 Get It

Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing
Feldman, Andrew L. , Smith, David I., Ansell, Stephen M. , Johnson, Sarah H. , Porcher, Julie C., Özsan, Nazan , Wieben, Eric D. , Eckloff, Bruce W., Vasmatzis, George , Doǧan, Ahmet , Smith, David I., Law, Mark E. , Feldman, Andrew L

Mayo Clinic

Blood | October 29, 2010 | Volume: 117 | Issue: 3 | Pages: 915-919

10.1182/blood-2010-08-303305 | PMID 21030553 Get It

Abstract The genetics of peripheral T-cell lymphomas are poorly understood. The most well-characterized abnormalities are translocations involving ALK, occurring in approximately half of anaplastic large cell lymphomas (ALCLs). To gain insight into the genetics of ALCLs lacking ALK translocations, we combined mate-pair DNA library construction, massively parallel (“Next Generation”) sequencing, and a novel bioinformatic algorithm. We identified a balanced translocation disrupting the DUSP22 phosphatase gene on 6p25.3 and adjoining the FRA7H fragile site on 7q32.3 in a systemic ALK-negative ALCL. Using fluorescence in situ hybridization, we demonstrated that the t(6;7)(p25.3;q32.3) was recurrent in ALK-negative ALCLs. Furthermore, t(6;7)(p25.3;q32.3) was associated with down-regulation of DUSP22 and up-regulation of MIR29 microRNAs on 7q32.3. These findings represent the first recurrent translocation reported in ALK-negative ALCL and highlight the utility of massively parallel genomic sequencing to discover novel translocations in lymphoma and other cancers.
A Recombinant Measles Virus Unable To Antagonize STAT1 Function Cannot Control Inflammation and Is Attenuated in Rhesus Monkeys
Devaux, Patricia , Hudacek, Andrew W., Hodge, Gregory, Valle, Jorge Reyes‐del, McChesney, Michael B., Cattaneo, Roberto

Mayo Clinic

Journal of Virology | October 28, 2010 | Volume: 85 | Issue: 1 | Pages: 348-356

10.1128/jvi.00802-10 | PMID 20980517 Get It

ABSTRACT Measles remains a leading cause of death worldwide among children because it suppresses immune function. The measles virus (MV) P gene encodes three proteins (P, V, and C) that interfere with innate immunity, controlling STAT1, STAT2, mda5, and perhaps other key regulators of immune function. We identified here three residues in the shared domain of the P and V proteins—tyrosine 110, valine 112, and histidine 115—that function to retain STAT1 in the cytoplasm and inhibit interferon transcription. This information was used to generate a recombinant measles virus unable to antagonize STAT1 function (STAT1-blind MV) differing only in these three residues from a wild-type strain of well-defined virulence. This virus was used to assess the relevance of P and V interactions with STAT1 for virulence in primates. When a group of six rhesus monkeys ( Macaca mulatta ) was inoculated intranasally with STAT1-blind MV, viremia was short-lived, and the skin rash and other clinical signs observed with wild-type MV were absent. The STAT1-blind virus less efficiently controlled the inflammatory response, as measured by enhanced transcription of interleukin-6 and tumor necrosis factor alpha in peripheral blood mononuclear cells from infected hosts. Importantly, neutralizing antibody titers and MV-specific T-cell responses were equivalent in hosts infected with either virus. These findings indicate that efficient MV interactions with STAT1 are required to sustain virulence in a natural host by controlling the inflammatory response against the virus. They also suggest that selectively STAT1-blind MV may have utility as vectors for targeted oncolysis and vaccination.
Dual-Source Dual-Energy CT With Additional Tin Filtration: Dose and Image Quality Evaluation in Phantoms and In Vivo
Primak, Andrew N. , Giraldo, Juan Carlos Ramírez, Eusemann, Christian D. , Schmidt, Bernhard , Kantor, Birgit, Fletcher, Joel G. , McCollough, Cynthia H.

Mayo Clinic

American Journal of Roentgenology | October 21, 2010 | Volume: 195 | Issue: 5 | Pages: 1164-1174

10.2214/ajr.09.3956 | PMID 20966323 Get It

Temporal response of canine flexor tendon to limb suspension
Sun, Yulong , Thoreson, Andrew R. , Cha, Stephen S., Zhao, Chunfeng, An, Kai‐Nan, Amadio, Peter C. , Cha, Stephen S.

Mayo Clinic

Journal of Applied Physiology | October 15, 2010 | Volume: 109 | Issue: 6 | Pages: 1762-1768

10.1152/japplphysiol.00051.2010 | PMID 20947711 Get It

Tendon disuse, or stress deprivation, frequently accompanies clinical disorders and treatments, yet the metabolism of tendons subject to stress deprivation has rarely been investigated systematically. The effects of stress deprivation on canine flexor tendon were investigated in this study. One adult canine forepaw was suspended for 21 or 42 days. Control forepaws were collected from dogs that had no intervention on their limbs and paws. The expression of collagen I and III was not significantly altered in the tendons disused for 21 days but was significantly decreased at 42 days ( P < 0.03). The expression of collagen II, aggrecan, decorin, and fibronectin was significantly decreased in the tendons in the suspended limbs at 21 days ( P < 0.002) and further reduced at 42 days. With stress deprivation, the expression of matrix metalloproteinase 2 (MMP2) was significantly increased ( P < 0.004) at 21 and 42 days. The expression of MMP3 was significantly decreased at 21 and 42 days ( P < 0.03). The expression of MMP13 was not altered with stress deprivation at 21 and 42 days. The expression of MMP14 was significantly increased at 21 days ( P = 0.0015) and returned to the control level at 42 days. Tissue inhibitor of metalloproteinase 1 (TIMP1) expression was decreased after the limbs were suspended for 42 days ( P = 0.0043), but not 21 days. However, TIMP2 expression was not significantly different from control at 21 or 42 days. Furthermore, the cross-sectional area of the stress-deprived tendons at 42 days was decreased compared with the control group ( P < 0.01). The intervention method in this study did not result in any alteration of stiffness of the tendon. Our study demonstrated that stress deprivation decreases the anabolic process and increases the catabolic process of extracellular matrix in flexor tendon.
Increasing Cardiac Troponin Changes Measured by a Research High-Sensitivity Troponin I Assay: Absolute vs Percentage Changes and Long-Term Outcomes in a Chest Pain Cohort
Kavsak, Peter A. , Ko, Dennis T. , MacRae, Andrew R., Jaffe, Allan S. , Wang, Xuesong , Jaffe, Allan S. , Kavsak, Peter

Mayo Clinic

Clinical Chemistry | October 13, 2010 | Volume: 56 | Issue: 12 | Pages: 1902-1904

10.1373/clinchem.2010.153486 | PMID 20940328 Get It

REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer
Comins, Charles, Spicer, James , Protheroe, Andrew , Roulstone, Victoria , Twigger, Katie, White, Christine , Vile, Richard G. , Melcher, Alan , Mettinger, K.L., Nuovo, Gerard J., Cohn, David E. , Phelps, Mitch A. , Harrington, Kevin J. , Pandha, Hardev , Coffey, Matt C. , Melcher, Alan A , Harrington, Kevin , Cohn, David , Phelps, Mitch

Mayo Clinic

Clinical Cancer Research | October 7, 2010 | Volume: 16 | Issue: 22 | Pages: 5564-5572

10.1158/1078-0432.ccr-10-1233 | PMID 20926400 Get It

Abstract Purpose: REOLYSIN (Oncolytics Biotech) consists of a wild-type oncolytic reovirus, which has selective cytotoxicity for tumor cells while sparing normal cells. In a phase I study as a single agent, repeated infusions of reovirus were safe with evidence of antitumor activity. Preclinical studies indicate potential for synergy between reovirus and chemotherapeutic agents. A multicenter, phase I dose escalation study was designed to assess the safety of combining reovirus with docetaxel chemotherapy in patients with advanced cancer. Experimental Design: Patients received 75 mg/m2 docetaxel (day 1) and escalating doses of reovirus up to 3 × 1010 TCID50 (days 1-5) every 3 weeks. Results: Twenty-five patients were enrolled, and 24 patients were exposed to treatment, with 23 completing at least one cycle and 16 suitable for response assessment. Dose-limiting toxicity of grade 4 neutropenia was seen in one patient, but the maximum tolerated dose was not reached. Antitumor activity was seen with one complete response and three partial responses. A disease control rate (combined complete response, partial response, and stable disease) of 88% was observed. Immunohistochemical analysis of reovirus protein expression was observed in posttreatment tumor biopsies from three patients. Conclusion: The combination of reovirus and docetaxel is safe, with evidence of objective disease response, and warrants further evaluation in a phase II study at a recommended schedule of docetaxel (75 mg/m2, three times weekly) and reovirus (3 × 1010 TCID50, days 1-5, every 3 weeks). Clin Cancer Res; 16(22); 5564–72. ©2010 AACR.